Novel drug database unifies the knowledge of drug research and development: More than 5000 scientific publications on clinical trials in humans and preclinical trials in animals concerning the bioavailability of drugs have been evaluated.
PharmaInformatic, a biotech-company based in Germany, has developed a comprehensive knowledge base on bioavailability, which enables the targeted development of drugs.
Several factors affect the oral bioavailability of drugs. For the first time, these can now be analysed in detail, thanks to a new resource. The new resource, called PACT-F (Preclinical And Clinical Trials Knowledge Base on Bioavailability) unifies the results and experiences of the last hundred years of drug research.
Oral bioavailability is one of the most important properties of a drug. If a new drug candidate has low or no oral bioavailability, further drug development will be stopped, because the candidate cannot be absorbed in the body.
The development of the knowledge base began in 2005. Since then the detailed results and conditions of more than 5000 scientific publications concerning the bioavailability of drugs have been evaluated and integrated into the database.
Each of the 8296 records contains the chemical structure of the investigated drug and up to seventeen additional fields, which describe in detail the experimental conditions of the trials (health status and number of subjects, gender, age, drug formulation, genetic differences, the species examined, route of administration, additional medication, method of measurement and further descriptions of the studies).
Dr Wolfgang Boomgaarden, founder and CEO of PharmaInformatic, says, ‚Our research is a huge step forward in the area of drug development and will improve the efficiency of clinical trials in humans. Fundamental new findings and conclusions can be derived from the knowledge base which will impact future drug discovery and development.‘
The knowledge base is a fundamental tool to develop computer models, which can predict the oral bioavailability of new drugs in humans, before clinical trials have to be conducted. This increases the prospects of new drugs and enhances the safety of clinical trials in humans.
PACT-F (Preclinical And Clinical Trials Knowledge Base on Bioavailability of Drugs)
PharmaInformatic provides ADME knowledge bases and expert systems to improve drug discovery and development. The company was founded in 2004 and is based in Emden, Germany. Further information is available at: http://www.pharmainformatic.com/html/products.html
Follow us on Twitter: https://twitter.com/PharmaInformati
Kontakt:
PharmaInformatic
Wolfgang Boomgaarden
Friesenstr. 36
26721 Emden
+49 (0)4921-99 33 60
presse@pharmainformatic.com
http://www.pharmainformatic.com